Lista de obras - Samantha Pozzi - Dominio Público Uruguay

5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells.

artículo científico publicado en 2007

A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up.

artículo científico publicado en 2016

A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function

artículo científico publicado en 2011

A simple and safe nomogram for the management of oral anticoagulation prior to minor surgery

artículo científico publicado en 2003

ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.

artículo científico publicado en 2009

AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition.

artículo científico

Absolute Monocyte Count and Lymphocyte-Monocyte Ratio Predict Outcome in Nodular Sclerosis Hodgkin Lymphoma: Evaluation Based on Data From 1450 Patients.

artículo científico publicado en 2015

Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients

artículo científico publicado en 2016

Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease

artículo científico publicado en 2010

Activity of BKM120 and BEZ235 against Lymphoma Cells.

artículo científico publicado en 2015

Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma

artículo científico publicado en 2009

Antimyeloma Activity of a Multitargeted Kinase Inhibitor, AT9283, via Potent Aurora Kinase and STAT3 Inhibition Either Alone or in Combination with Lenalidomide ⬇️

artículo científico publicado el 23 de marzo de 2011

Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.

artículo científico publicado en 2016

Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts.

artículo científico publicado en 2005

Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients.

artículo científico publicado en 2007

Bisphosphonates and Atypical Femoral Fractures ⬇️

artículo científico publicado el 9 de septiembre de 2010

Bisphosphonates-associated osteonecrosis of the jaw: A long-term follow-up of a series of 35 cases observed by GISL and evaluation of its frequency over time.

artículo científico publicado en 2009

Cell-Penetrating CaCO₃ Nanocrystals for Improved Transport of NVP-BEZ235 across Membrane Barrier in T-Cell Lymphoma

artículo científico publicado en 2018

Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy.

artículo científico publicado en 2014

Dialysis-dependent renal failure at diagnosis continues to be associated with very poor outcome in multiple myeloma - response to Murphyet al

scientific article published on 06 March 2014

Fatty acid synthase is a novel therapeutic target in multiple myeloma

artículo científico publicado en 2008

In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma.

artículo científico publicado en 2013

Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients

artículo científico publicado en 2007

MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.

artículo científico publicado en 2007

Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era

artículo científico publicado en 2013

Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas

artículo científico publicado en 2013

NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy.

artículo científico publicado en 2012

Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: results of a large multicenter study involving 990 patients

artículo científico publicado en 2016

Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice

artículo científico publicado en 2008

Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma

artículo científico publicado en 2009

Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story.

artículo científico publicado en 2009

Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study.

artículo científico publicado en 2007

Risk of Second Primary Malignancy in Breast Cancer Survivors: A Nested Population-Based Case-Control Study.

artículo científico publicado en 2015

Role of thalidomide in previously untreated patients with multiple myeloma.

scientific article published on October 2008

Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi

artículo científico publicado en 2016

Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study.

artículo científico publicado en 2008

Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study.

artículo científico publicado en 2008

Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis.

artículo científico publicado en 2013

The Role of Bisphosphonates in Multiple Myeloma: Mechanisms, Side Effects, and the Future ⬇️

artículo científico publicado el 14 de abril de 2011

The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines.

artículo científico publicado en 2014

The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines

artículo científico publicado en 2016

The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo

artículo científico publicado en 2009

The potential of pralatrexate as a treatment of peripheral T-cell lymphoma.

artículo científico

Lista de obras de Samantha Pozzi

5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells.

A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up.

A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function

A simple and safe nomogram for the management of oral anticoagulation prior to minor surgery

ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.

AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition.

Absolute Monocyte Count and Lymphocyte-Monocyte Ratio Predict Outcome in Nodular Sclerosis Hodgkin Lymphoma: Evaluation Based on Data From 1450 Patients.

Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients

Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease

Activity of BKM120 and BEZ235 against Lymphoma Cells.

Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma

Antimyeloma Activity of a Multitargeted Kinase Inhibitor, AT9283, via Potent Aurora Kinase and STAT3 Inhibition Either Alone or in Combination with Lenalidomide ⬇️

Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.

Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts.

Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients.

Bisphosphonates and Atypical Femoral Fractures ⬇️

Bisphosphonates-associated osteonecrosis of the jaw: A long-term follow-up of a series of 35 cases observed by GISL and evaluation of its frequency over time.

Cell-Penetrating CaCO₃ Nanocrystals for Improved Transport of NVP-BEZ235 across Membrane Barrier in T-Cell Lymphoma

Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy.

Dialysis-dependent renal failure at diagnosis continues to be associated with very poor outcome in multiple myeloma - response to Murphyet al

Fatty acid synthase is a novel therapeutic target in multiple myeloma

In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma.

Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients

MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.

Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era

Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas

NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy.

Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: results of a large multicenter study involving 990 patients

Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice

Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma

Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story.

Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study.

Risk of Second Primary Malignancy in Breast Cancer Survivors: A Nested Population-Based Case-Control Study.

Role of thalidomide in previously untreated patients with multiple myeloma.

Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi

Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study.

Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study.

Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis.

The Role of Bisphosphonates in Multiple Myeloma: Mechanisms, Side Effects, and the Future ⬇️

The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines.

The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines

The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo

The potential of pralatrexate as a treatment of peripheral T-cell lymphoma.